Any feedback?
Information on EC 3.1.4.2 - glycerophosphocholine phosphodiesterase and Organism(s) Homo sapiens and UniProt Accession Q8WTR4
for references in articles please use BRENDA:EC3.1.4.2Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
3.1.4.2 glycerophosphocholine phosphodiesteraseIUBMB Comments
Also acts on sn-glycero-3-phosphoethanolamine.
Specify your search results
Word Map
- 3.1.4.2
- surfactant
- pulmonary
- influenza
- haemophilus
- pneumonia
- alveolar
- pneumococcal
- lectin
-
collectins
-
lavage
- children
- airway
-
bronchoalveolar
-
c-type
-
phid-cv
- otitis
-
interstitial
- infant
-
serotypes
- collagen
-
10-valent
-
non-typeable
- bal
-
agglutination
- nasopharyngeal
-
booster
-
mannose-binding
-
protein-d
-
conglutinin
-
clara
-
distress
-
surfactant-associated
- diagnostics
-
pneumolysin
-
mannan-binding
- toxoid
-
reactogenicity
- medicine
-
airspace
-
serotype-specific
-
spirometry
- emphysema
-
collagen-like
-
non-vaccine
-
dodecamers
-
lung-specific
-
glaxosmithkline
-
choline-binding
- proteinosis
-
opsonophagocytic
- biotechnology
-
lungen-6
-
srage
- drug development
The taxonomic range for the selected organisms is: Homo sapiens
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria, Archaea
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria, Archaea
Synonyms
protein d, gdpd5, glycerophosphodiesterase, gdpase, enpp6, glycerophosphocholine phosphodiesterase, gpx-pde, gdpd6, gpc diesterase, gpc:choline phosphodiesterase, 
more
top
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
glycerolphosphorylcholine phosphodiesterase
-
-
-
-
glycerophosphinicocholine diesterase
-
-
-
-
glycerophosphocholinehydrolase
-
-
-
-
glycerylphosphorylcholinediesterase
-
-
-
-
sn-glycero 3-phosphorylcholine diesterase
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hydrolysis of phosphoric ester
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
sn-glycero-3-phosphocholine glycerophosphohydrolase
Also acts on sn-glycero-3-phosphoethanolamine.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
9025-85-8
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
sn-glycero-3-phosphocholine + H2O
choline + sn-glycerol 3-phosphate
-
-
-
?
sn-glycero 3-phosphorylcholine + H2O
?
-
cellular phosphatidylcholine catabolic pathway
-
-
?
sn-glycero 3-phosphorylcholine + H2O
sn-glycerol 3-phosphate + choline
-
only found in autopsied tissue
-
?
sn-glycero 3-phosphorylethanolamine + H2O
?
-
cellular phosphatidyethanolamine catabolic pathway
-
-
?
sn-glycero 3-phosphorylethanolamine + H2O
sn-glycerol 3-phosphate + ethanolamine
-
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
sn-glycero-3-phosphocholine + H2O
choline + sn-glycerol 3-phosphate
-
-
-
?
sn-glycero 3-phosphorylcholine + H2O
?
-
cellular phosphatidylcholine catabolic pathway
-
-
?
sn-glycero 3-phosphorylethanolamine + H2O
?
-
cellular phosphatidyethanolamine catabolic pathway
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
glycero 3-phosphorylethanolamine
-
45% inhibition of choline formation in equimolar ratio to glycerophosphorylcholine
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Abortion, Missed
Serum Levels of Collectins Are Sustained During Pregnancy: Surfactant Protein D Levels Are Dysregulated Prior to Missed Abortion.
Acquired Immunodeficiency Syndrome
AIDS patients have increased surfactant protein D but normal mannose binding lectin levels in lung fluid.
Acute Kidney Injury
Innate immune molecule surfactant protein D attenuates sepsis-induced acute kidney injury through modulating apoptosis and NF?B-mediated inflammation.
Acute Kidney Injury
Surfactant protein D (SP-D) gene polymorphism rs721917 is an independent predictor of acute kidney injury development in sepsis patients: a prospective cohort study.
Acute Lung Injury
Anti-inflammatory and antioxidant effects of infliximab on acute lung injury in a rat model of intestinal ischemia/reperfusion.
Acute Lung Injury
Depletion of circulating monocytes suppresses IL-17 and HMGB1 expression in mice with LPS-induced acute lung injury.
Acute Lung Injury
Differential modulation of surfactant protein D under acute and persistent hypoxia in acute lung injury.
Acute Lung Injury
Effect of dexamethasone on the content of pulmonary surfactant protein D in young rats with acute lung injury induced by lipopolysaccharide.
Acute Lung Injury
Effect of Single versus Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis.
Acute Lung Injury
Lower Oligomeric Form of Surfactant Protein D in Murine Acute Lung Injury Induces M1 Subtype Macrophages Through Calreticulin/p38 MAPK Signaling Pathway.
Acute Lung Injury
PLASMA BIOMARKER PROFILES IN ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS.
Acute Lung Injury
Prognostic value of surfactant proteins A and D in patients with acute lung injury.
Acute Lung Injury
Protective effect of curcumin on acute lung injury induced by intestinal ischemia/reperfusion.
Acute Lung Injury
Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity.
Acute Lung Injury
Surfactant phospholipids, surfactant proteins, and inflammatory markers during acute lung injury in children.
Acute Lung Injury
Surfactant protein D gene regulation. Interactions among the conserved CCAAT/enhancer-binding protein elements.
Acute Lung Injury
Surfactant protein D is a useful biomarker for monitoring acute lung injury in rats.
Adenocarcinoma
High expression of Helicobacter pylori VapD in both the intracellular environment and biopsies from gastric patients with severity.
Alveolitis, Extrinsic Allergic
Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis.
Alveolitis, Extrinsic Allergic
Mushroom worker's lung caused by spores of Hypsizigus marmoreus (Bunashimeji): elevated serum surfactant protein D levels.
Alveolitis, Extrinsic Allergic
The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis.
Anemia, Sickle Cell
Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
Anemia, Sickle Cell
Surfactant protein D as a marker for pulmonary complications in pediatric patients with sickle cell disease: Relation to lung function tests.
Arthritis, Rheumatoid
Circadian rhythm and the influence of physical activity on circulating surfactant protein D in early and long-standing rheumatoid arthritis.
Arthritis, Rheumatoid
Circulating surfactant protein D is decreased in early rheumatoid arthritis: a 1-year prospective study.
Asbestosis
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
Aspergillosis, Allergic Bronchopulmonary
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis.
Asthma
Amino acid variants in Surfactant protein D are not associated with bronchial asthma.
Asthma
Impact of a Met(11)Thr single nucleotide polymorphism of surfactant protein D on allergic airway inflammation in a murine asthma model.
Asthma
Increased surfactant protein D in rat airway goblet and Clara cells during ovalbumin-induced allergic airway inflammation.
Asthma
Mouse Strain-Dependent Difference Toward the Staphylococcus aureus Allergen Serine Protease-Like Protein D Reveals a Novel Regulator of IL-33.
Asthma
Perinatal biomarkers implying 'Developmental Origins of Health and Disease' consequences in intrauterine growth restriction.
Asthma
Sputum and BAL Clara cell secretory protein and Surfactant protein D levels in asthma.
Asthma
Therapeutic effect of surfactant protein D in allergic inflammation of mite-sensitized mice.
Asthma
[The total content and oligomeric transformations of surfactant protein d in bronchoalveolar lavage fluid in bronchial asthma and gastroesophageal reflux disease: the role in deterioration of the immune response].
Atherosclerosis
Association between the surfactant protein D (SFTPD) gene and subclinical carotid artery atherosclerosis.
Atherosclerosis
Serum Surfactant Protein D is Associated with Atherosclerosis of the Carotid Artery in Patients on Maintenance Hemodialysis.
Bacterial Infections
Inhibition of neutrophil elastase reduces lung injury and bacterial count in hamsters.
Blister
Surfactant protein D regulates caspase-8-mediated cascade of the intrinsic pathway of apoptosis while promoting bleb formation.
Brain Neoplasms
CRP-ductin, the mouse homologue of gp-340/deleted in malignant brain tumors 1 (DMBT1), binds gram-positive and gram-negative bacteria and interacts with lung surfactant protein D.
Breast Neoplasms
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
Breast Neoplasms
Hyaluronic Acid Present in the Tumor Microenvironment Can Negate the Pro-apototic Effect of a Recombinant Fragment of Human Surfactant Protein D on Breast Cancer Cells.
Breast Neoplasms
Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.
Breast Neoplasms
Targeting choline phospholipid metabolism: GDPD5 and GDPD6 silencing decrease breast cancer cell proliferation, migration, and invasion.
Bronchiectasis
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.
Bronchiectasis
Paediatric and adult bronchiectasis: Vaccination in prevention and management.
Bronchiectasis
The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial.
Bronchiolitis Obliterans
Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation.
Bronchitis
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.
Bronchitis
The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial.
Bronchitis, Chronic
Sequence variation in the hpd gene of nonencapsulated Haemophilus influenzae isolated from patients with chronic bronchitis.
Bronchopulmonary Dysplasia
Serum surfactant protein D as a marker for bronchopulmonary dysplasia.
Bronchopulmonary Dysplasia
Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem.
Carcinogenesis
Circ_0007142 downregulates miR-874-3p-mediated GDPD5 on colorectal cancer cells.
Carcinoma
Opposite effects of tumor protein D (TPD) 52 and TPD54 on oral squamous cell carcinoma cells.
Carcinoma, Non-Small-Cell Lung
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
Cardiovascular Diseases
Serum surfactant protein D is associated with the prognosis in patients with chronic kidney disease.
Cardiovascular Diseases
Surfactant protein D is not so friendly outside the lung-aggravation of cardiovascular disease.
Cervical Intraepithelial Neoplasia
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Chronic Periodontitis
Increased plasma concentration of surfactant protein D in chronic periodontitis independent of SFTPD genotype: potential role as a biomarker.
Coinfection
Intranasal coinfection model allows for assessment of protein vaccines against nontypeable Haemophilus influenzae in mice.
Colitis, Ulcerative
Genetic variants in surfactant, pulmonary-associated protein D (SFTPD) and Japanese susceptibility to ulcerative colitis.
Collagen Diseases
Comparative evaluation of KL-6 and surfactant protein D as serum markers for interstitial pneumonia associated with collagen diseases.
Colonic Neoplasms
Association of surfactant protein D with pulmonary metastases from colon cancer.
Colorectal Neoplasms
Circ_0007142 downregulates miR-874-3p-mediated GDPD5 on colorectal cancer cells.
Colorectal Neoplasms
GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Communicable Diseases
Innate Immune Molecule Surfactant Protein D Attenuates Sepsis-induced Acute Pancreatic Injury through Modulating Apoptosis and NF-?B-mediated Inflammation.
Connective Tissue Diseases
Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis.
Coronary Artery Disease
Serum surfactant protein D is associated with the prognosis in patients with chronic kidney disease.
COVID-19
Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19?
COVID-19
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
COVID-19
Expression of Surfactant Protein D Distinguishes Severe Pandemic Influenza A(H1N1) from Coronavirus Disease 2019.
COVID-19
Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity.
Cryptococcosis
Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis.
Cystic Fibrosis
Genetic Association With Pseudomonas aeruginosa Acquisition in Cystic Fibrosis: Influence of Surfactant Protein D and Mannose-Binding Lectin.
Cystic Fibrosis
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis.
Cystic Fibrosis
The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.
Dementia
Serum surfactant protein D is correlated to development of dementia and augmented mortality.
Dermatomyositis
Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease.
Diabetes Mellitus, Type 2
Serum Surfactant Protein D as a Biomarker for Measuring Lung Involvement in Obese Type 2 Diabetic Patients.
Diphtheria
A physico-chemical assessment of the thermal stability of pneumococcal conjugate vaccine components.
Diphtheria
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
Diphtheria
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Diphtheria
Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen.
Diphtheria
Protein carriers of conjugate vaccines: Characteristics, development and clinical trials.
Diphtheria
Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Diphtheria
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Diphtheria
The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials.
Dry Eye Syndromes
Surfactant protein D contributes to ocular defense against pseudomonas aeruginosa in a murine model of dry eye disease.
Endometrial Neoplasms
EDI3 links choline metabolism to integrin expression, cell adhesion and spreading.
Endotoxemia
Surfactant protein d deficiency in mice is associated with hyperphagia, altered fat deposition, insulin resistance, and increased basal endotoxemia.
Eosinophilia
Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis.
Eosinophilia
Ozone-induced enhancement of airway hyperreactivity in rhesus macaques: Effects of antioxidant treatment.
Farmer's Lung
Mushroom worker's lung caused by spores of Hypsizigus marmoreus (Bunashimeji): elevated serum surfactant protein D levels.
Fetal Growth Retardation
The Effect of Intrauterine Growth Restriction on Circulating Surfactant Protein D Concentrations in the Perinatal Period.
Gastroesophageal Reflux
[Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux].
Gastroesophageal Reflux
[The total content and oligomeric transformations of surfactant protein d in bronchoalveolar lavage fluid in bronchial asthma and gastroesophageal reflux disease: the role in deterioration of the immune response].
glycerophosphocholine phosphodiesterase deficiency
Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis.
glycerophosphocholine phosphodiesterase deficiency
Surfactant protein d deficiency in mice is associated with hyperphagia, altered fat deposition, insulin resistance, and increased basal endotoxemia.
glycerophosphocholine phosphodiesterase deficiency
Surfactant Protein D Deficiency Increases Lung Injury during Endotoxemia.
glycerophosphocholine phosphodiesterase deficiency
Surfactant protein D deficiency influences allergic immune responses.
Glycogen Storage Disease Type VI
Rapidly progressive organizing pneumonia associated with COVID-19.
Hearing Loss
Identification of Novel Candidate Genes and Variants for Hearing Loss and Temporal Bone Anomalies.
Helicobacter Infections
Helicobacter infection in the surfactant protein D-deficient mouse.
Hemorrhagic Fever, Ebola
Involvement of Surfactant Protein D in Ebola Virus Infection Enhancement via Glycoprotein Interaction.
Hepatitis A
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
Hepatitis A
Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children.
Hepatitis A
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Hepatitis B
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Hepatitis B
Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial.
Hepatitis B
Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Hepatitis B
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Hepatitis C
Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda.
Hepatitis E
New route for fast detection of antibodies against zoonotic pathogens in sera of slaughtered pigs by means of flow-through chemiluminescence immunochips.
Herpes Zoster
Interactions between rat alveolar epithelial cells and bone marrow-derived mesenchymal stem cells: an in vitro co-culture model.
HIV Infections
HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D.
HIV Infections
Surfactant Protein D Modulates HIV Infection of Both T-Cells and Dendritic Cells.
Hypersensitivity
Linking surfactant protein SP-D and IL-13: implications in asthma and allergy.
Hypersensitivity
Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens.
Hypersensitivity
Recombinant Fragment of Human Surfactant Protein D: A Hierarchical Regulator of Pulmonary Hypersensitivity.
Hypersensitivity
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis.
Hypersensitivity
Surfactant protein SP-D modulates activity of immune cells: proteomic profiling of its interaction with eosinophilic cells.
Idiopathic Interstitial Pneumonias
Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy.
Idiopathic Pulmonary Fibrosis
Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan.
Idiopathic Pulmonary Fibrosis
Comparative Proteomic Analysis of Rat Bronchoalveolar Lavage Fluid after Exposure to Zinc Oxide Nanoparticles.
Idiopathic Pulmonary Fibrosis
Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
Effect of Single versus Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis.
Idiopathic Pulmonary Fibrosis
Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Idiopathic Pulmonary Fibrosis
Letter to the Editor: Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Idiopathic Pulmonary Fibrosis
PLASMA BIOMARKER PROFILES IN ACUTE EXACERBATION OF IDIOPATHIC PULMONARY FIBROSIS.
Idiopathic Pulmonary Fibrosis
Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Idiopathic Pulmonary Fibrosis
Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan.
Idiopathic Pulmonary Fibrosis
Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Idiopathic Pulmonary Fibrosis
Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia.
Infections
A Unique Sugar-binding Site Mediates the Distinct Anti-influenza Activity of Pig Surfactant Protein D.
Infections
Altered Gut Microbiota Composition in Subjects Infected With Clonorchis sinensis.
Infections
Chlamydia psittaci PmpD-N Exacerbated Chicken Macrophage Function by Triggering Th2 Polarization and the TLR2/MyD88/NF-?B Signaling Pathway.
Infections
Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia.
Infections
Differential expression of ovine innate immune genes by preterm and neonatal lung epithelia infected with respiratory syncytial virus.
Infections
Dipeptidyl peptidase I controls survival from Klebsiella pneumoniae lung infection by processing surfactant protein D.
Infections
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
Infections
Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures.
Infections
Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection.
Infections
Enhanced Antiviral Activity of Human Surfactant Protein D by Site-Specific Engineering of the Carbohydrate Recognition Domain.
Infections
Expression of surfactant protein D in the human gastric mucosa and during Helicobacter pylori infection.
Infections
Functional Analysis of Genetic Variations in Surfactant Protein D in Mycobacterial Infection and Their Association With Tuberculosis.
Infections
Histone H4 potentiates neutrophil inflammatory responses to influenza A virus: Down-modulation by H4 binding to C-reactive protein and Surfactant protein D.
Infections
Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
Infections
Impact of neutrophils on antiviral activity of human bronchoalveolar lavage fluid.
Infections
In vivo evaluation of adeno-associated virus gene transfer in airways of mice with acute or chronic respiratory infection.
Infections
Inhibition of competence development, horizontal gene transfer and virulence in Streptococcus pneumoniae by a modified competence stimulating peptide.
Infections
Innate defense against influenza A virus: activity of human neutrophil defensins and interactions of defensins with surfactant protein D.
Infections
Lectin-mediated binding and sialoglycans of porcine surfactant protein D synergistically neutralize influenza A virus.
Infections
Local and systemic antibody levels against protein D of Haemophilus influenzae following immunization and infection in rats.
Infections
Protective Role of Surfactant Protein D in Ocular Staphylococcus aureus Infection.
Infections
Pulmonary infections in swine induce altered porcine surfactant protein D expression and localization to dendritic cells in bronchial-associated lymphoid tissue.
Infections
Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.
Infections
Pulmonary Surfactant Protein D in First-Line Innate Defence against Influenza A Virus Infections.
Infections
Recombinant polymorphic membrane protein D in combination with a novel, second-generation lipid adjuvant protects against intra-vaginal Chlamydia trachomatis infection in mice.
Infections
Reduced influenza viral neutralizing activity of natural human trimers of surfactant protein D.
Infections
Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine.
Infections
Respiratory tract infections in diabetic and non-diabetic individuals are linked with serum surfactant protein-D.
Infections
Serine-Aspartate Repeat Protein D Increases Staphylococcus aureus Virulence and Survival in Blood.
Infections
Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children.
Infections
Serum Concentrations of Antibodies against Outer Membrane Protein P6, Protein D, and T- and B-Cell Combined Antigenic Epitopes of Nontypeable Haemophilus influenzae in Children and Adults of Different Ages.
Infections
Sialylation of outer membrane porin protein D: a mechanistic basis of antibiotic uptake in Pseudomonas aeruginosa.
Infections
Structural requirements for SP-D function in vitro and in vivo: therapeutic potential of recombinant SP-D.
Infections
Surfactant Protein D Binds to Coxiella burnetii and Results in a Decrease in Interactions with Murine Alveolar Macrophages.
Infections
Surfactant protein D contributes to ocular defense against pseudomonas aeruginosa in a murine model of dry eye disease.
Infections
Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection.
Infections
Surfactant protein D inhibits HIV-1 infection of target cells via interference with gp120-CD4 interaction and modulates pro-inflammatory cytokine production.
Infections
Surfactant protein D is present in the human female reproductive tract and inhibits Chlamydia trachomatis infection.
Infections
Surfactant protein SP-D modulates activity of immune cells: proteomic profiling of its interaction with eosinophilic cells.
Infections
The association of PM2.5 with airway innate antimicrobial activities of salivary agglutinin and surfactant protein D.
Infections
The Chlamydia trachomatis PmpD adhesin forms higher order structures through disulphide-mediated covalent interactions.
Infections
The production mechanism and immunosuppression effect of pulmonary surfactant protein D via toll like receptor 4 signaling pathway in human corneal epithelial cells during Aspergillus fumigatus infection.
Infections
The role of surfactant protein D in the colonisation of the respiratory tract and onset of bacteraemia during pneumococcal pneumonia.
Infections
The roles of surfactant protein D during Aspergillus fumigatus infection in human corneal epithelial cells.
Inflammatory Bowel Diseases
Colonic Epithelial Surfactant Protein D Expression Correlates with Inflammation in Clinical Colonic Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Genetic variants in surfactant, pulmonary-associated protein D (SFTPD) and Japanese susceptibility to ulcerative colitis.
Influenza in Birds
Decreased expression of surfactant protein D mRNA in human lungs in fatal cases of H5N1 avian influenza.
Influenza, Human
Assessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitro.
Influenza, Human
Assessment of the antiviral properties of recombinant surfactant protein D against influenza B virus in vitro.
Influenza, Human
A reduced expression of surfactant protein D in the lungs of fatal influenza H1N1 cases in 2009.
Influenza, Human
Critical role for cross-linking of trimeric lectin domains of surfactant protein D in antiviral activity against influenza A virus.
Influenza, Human
Effects of Vaccination with 10-Valent Pneumococcal Non-Typeable Haemophilus influenza Protein D Conjugate Vaccine (PHiD-CV) on the Nasopharyngeal Microbiome of Kenyan Toddlers.
Influenza, Human
Enhanced Antiviral Activity of Human Surfactant Protein D by Site-Specific Engineering of the Carbohydrate Recognition Domain.
Influenza, Human
Enhancement of antiviral activity of collectin trimers through cross-linking and mutagenesis of the carbohydrate recognition domain.
Influenza, Human
Entry Inhibition and Modulation of Pro-Inflammatory Immune Response Against Influenza A Virus by a Recombinant Truncated Surfactant Protein D.
Influenza, Human
Evidence for a protective role of pulmonary surfactant protein D (SP-D) against influenza A viruses.
Influenza, Human
Expression of Surfactant Protein D Distinguishes Severe Pandemic Influenza A(H1N1) from Coronavirus Disease 2019.
Influenza, Human
Histone H4 potentiates neutrophil inflammatory responses to influenza A virus: Down-modulation by H4 binding to C-reactive protein and Surfactant protein D.
Influenza, Human
Impact of neutrophils on antiviral activity of human bronchoalveolar lavage fluid.
Influenza, Human
Increased antiviral and opsonic activity of a highly multimerized collectin chimera.
Influenza, Human
Influenza Virus Hemagglutinins H2, H5, H6, and H11 Are Not Targets of Pulmonary Surfactant Protein D: N-Glycan Subtypes in Host-Pathogen Interactions.
Influenza, Human
Innate defense against influenza A virus: activity of human neutrophil defensins and interactions of defensins with surfactant protein D.
Influenza, Human
Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D.
Influenza, Human
Interactions of influenza A virus with sialic acids present on porcine surfactant protein D.
Influenza, Human
Interactions of recombinant human pulmonary surfactant protein D and SP-D multimers with influenza A.
Influenza, Human
Introduction of N-linked glycans in the lectin domain of surfactant protein D: impact on interactions with influenza A viruses.
Influenza, Human
Lectin-mediated binding and sialoglycans of porcine surfactant protein D synergistically neutralize influenza A virus.
Influenza, Human
Ligand specificity of human surfactant protein D: expression of a mutant trimeric collectin that shows enhanced interactions with influenza A virus.
Influenza, Human
Mechanism of binding of surfactant protein D to influenza A viruses: importance of binding to haemagglutinin to antiviral activity.
Influenza, Human
Molecular mechanisms of inhibition of influenza by surfactant protein D revealed by large-scale molecular dynamics simulation.
Influenza, Human
Monoclonal antibody-assisted structure-function analysis of the carbohydrate recognition domain of surfactant protein D.
Influenza, Human
Multimerization of surfactant protein D, but not its collagen domain, is required for antiviral and opsonic activities related to influenza virus.
Influenza, Human
Mutagenesis of surfactant protein D informed by evolution and x-ray crystallography enhances defenses against influenza A virus in vivo.
Influenza, Human
MUTATIONS FLANKING THE CARBOHYDRATE BINDING SITE OF SURFACTANT PROTEIN D CONFER ANTIVIRAL ACTIVITY FOR PANDEMIC INFLUENZA A VIRUSES.
Influenza, Human
Neuraminidase Activity and The Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.
Influenza, Human
Paediatric and adult bronchiectasis: Vaccination in prevention and management.
Influenza, Human
Pulmonary Surfactant Protein D in First-Line Innate Defence against Influenza A Virus Infections.
Influenza, Human
Recognition of mannosylated ligands and influenza a virus by human surfactant protein D: contributions of an extended site and residue 343.
Influenza, Human
Recombinant porcine surfactant protein D inhibits influenza A virus replication ex vivo.
Influenza, Human
Reduced influenza viral neutralizing activity of natural human trimers of surfactant protein D.
Influenza, Human
Reduction of Streptococcus pneumoniae in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish county.
Influenza, Human
Response to Letter to the Editor: Detection of naturally occurring antibodies against Protein D of Haemophilus influenza by Mustafa Akkoyunlu.
Influenza, Human
Role of viral hemagglutinin glycosylation in anti-influenza activities of recombinant surfactant protein D.
Influenza, Human
Serum KL-6 and SP-D in children with 2009 pandemic H1N1 influenza infection.
Influenza, Human
Structure of a truncated human surfactant protein D is less effective in agglutinating bacteria than the native structure and fails to inhibit haemagglutination by influenza A virus.
Influenza, Human
Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophages.
Influenza, Human
Surfactant protein D enhances clearance of influenza A virus from the lung in vivo.
Influenza, Human
The ability of pandemic influenza virus hemagglutinins to induce lower respiratory pathology is associated with decreased surfactant protein D binding.
Influenza, Human
The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins.
Influenza, Human
The number and position of N-linked glycosylation sites in the hemagglutinin determine differential recognition of seasonal and 2009 pandemic H1N1 influenza virus by porcine surfactant protein D.
Influenza, Human
The Role and Molecular Mechanism of Action of Surfactant Protein D in Innate Host Defense Against Influenza A Virus.
Insulin Resistance
Surfactant protein d deficiency in mice is associated with hyperphagia, altered fat deposition, insulin resistance, and increased basal endotoxemia.
Insulin Resistance
Surfactant protein d, a marker of lung innate immunity, is positively associated with insulin sensitivity.
Intellectual Disability
Identification of microduplications at Xp21.2 and Xq13.1 in neurodevelopmental disorders.
Invasive Pulmonary Aspergillosis
Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis.
Invasive Pulmonary Aspergillosis
Therapeutic effects of recombinant forms of full-length and truncated human surfactant protein D in a murine model of invasive pulmonary aspergillosis.
Kidney Failure, Chronic
Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency.
Leukomalacia, Periventricular
Intranasal surfactant protein D as neuroprotective rescue in a neonatal rat model of periventricular leukomalacia.
Leukomalacia, Periventricular
Surfactant protein D as a novel therapy for periventricular leukomalacia: is it the missing piece of the puzzle?
Lipidoses
Reversibility of pulmonary abnormalities by conditional replacement of surfactant protein D (SP-D) in vivo.
Lipoid Proteinosis of Urbach and Wiethe
Surfactant protein D. Increased accumulation in silica-induced pulmonary lipoproteinosis.
Liver Diseases
Immunolocalization of surfactant protein D in the liver from infants with cholestatic liver disease.
Lung Diseases
Candidate Gene Analysis of the Surfactant Protein D Gene in Pediatric Diffuse Lung Disease.
Lung Diseases
Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Lung Diseases
Comparative evaluation of heterologous production systems for recombinant pulmonary surfactant protein D.
Lung Diseases
Does a 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine prevent respiratory exacerbations in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: protocol for a randomised controlled trial.
Lung Diseases
Donor surfactant protein D (SP-D) polymorphisms are associated with lung transplant outcome.
Lung Diseases
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis.
Lung Diseases
Genetic associations of surfactant protein D and angiotensin-converting enzyme with lung disease in preterm neonates.
Lung Diseases
Improving immunity to Haemophilus influenzae in children with chronic suppurative lung disease.
Lung Diseases
Patterns of neutrophil serine protease-dependent cleavage of surfactant protein D in inflammatory lung disease.
Lung Diseases
Reversibility of pulmonary abnormalities by conditional replacement of surfactant protein D (SP-D) in vivo.
Lung Diseases
Serum Surfactant Protein D as a Biomarker for Measuring Lung Involvement in Obese Type 2 Diabetic Patients.
Lung Diseases
Surfactant protein A and surfactant protein D variation in pulmonary disease.
Lung Diseases
Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease.
Lung Diseases
Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure.
Lung Diseases
Surfactant Protein-D: A sensitive predictor for efficiency of preoperative pulmonary rehabilitation.
Lung Diseases
The clinical, immunological and microbiological impact of the 10-valent pneumococcal-Protein D conjugate vaccine in children with recurrent protracted bacterial bronchitis, chronic suppurative lung disease and bronchiectasis: A multi-centre, double-blind, randomised controlled trial.
Lung Diseases
The evaluation of serum surfactant protein D (SP-D) levels as a biomarker of lung injury in tuberculosis and different lung diseases.
Lung Diseases
The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.
Lung Diseases, Interstitial
A case of interstitial pneumonia caused by bucillamine: a study using serological markers.
Lung Diseases, Interstitial
Analysis of immune reconstitution after autologous CD34+ stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells.
Lung Diseases, Interstitial
Association between genetic variations in surfactant protein d and emphysema, interstitial pneumonia, and lung cancer in a Japanese population.
Lung Diseases, Interstitial
Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?
Lung Diseases, Interstitial
Clinical significance of serum surfactant protein D (SP-D) in patients with polymyositis/dermatomyositis: correlation with interstitial lung disease.
Lung Diseases, Interstitial
Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia.
Lung Diseases, Interstitial
Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis.
Lung Diseases, Interstitial
Comparative evaluation of KL-6 and surfactant protein D as serum markers for interstitial pneumonia associated with collagen diseases.
Lung Diseases, Interstitial
Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
Lung Diseases, Interstitial
Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Lung Diseases, Interstitial
Involvement of eicosanoids and surfactant protein D in extrinsic allergic alveolitis.
Lung Diseases, Interstitial
KL-6, surfactant protein A and D in bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis.
Lung Diseases, Interstitial
Pneumocyte Biomarkers KL-6 and Surfactant Protein D Reflect the Distinct Findings of High-Resolution Computed Tomography in Nonspecific Interstitial Pneumonia.
Lung Diseases, Interstitial
Pulmonary effects in workers exposed to indium metal: A cross-sectional study.
Lung Diseases, Interstitial
Radiation pneumonitis after stereotactic radiation therapy for lung cancer.
Lung Diseases, Interstitial
Rapidly progressive organizing pneumonia associated with COVID-19.
Lung Diseases, Interstitial
Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Lung Diseases, Interstitial
Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease.
Lung Diseases, Interstitial
Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
Lung Diseases, Interstitial
Surfactant protein D is associated with 3-month mortality of anti-MDA5 antibody-interstitial lung disease.
Lung Diseases, Interstitial
The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis.
Lung Diseases, Interstitial
[Assessment of serum markers KL-6 and SP-D for interstitial pneumonia associated with connective tissue diseases]
Lung Diseases, Interstitial
[Valproate sodium and zonisamide associated interstitial pneumonitis in an infant]
Lung Diseases, Obstructive
Surfactant protein D in chornic obstructive pulmonary disease (COPD).
Lung Injury
A Potential Biomarker for Predicting the Risk of Radiation-Induced Fibrosis in the Lung.
Lung Injury
Altered expression of cyclooxygenase-2, 12-lipoxygenase, inducible nitric oxide synthase-2 and surfactant protein D in lungs of patients with pulmonary injury caused by sulfur mustard.
Lung Injury
Biomarkers for lung epithelium injury in occupational hexavalent chromium-exposed workers.
Lung Injury
Efficient resolution of Pneumocystis murina infection in surfactant protein A-deficient mice following withdrawal of corticosteroid-induced immunosuppression.
Lung Injury
Intranasal Bifidobacterium longum protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection.
Lung Injury
Lung Surfactant Protein D (SP-D) Response and Regulation During Acute and Chronic Lung Injury.
Lung Injury
Plasma levels of surfactant protein D and KL-6 for evaluation of lung injury in critically ill mechanically ventilated patients.
Lung Injury
Proximal promoter of the surfactant protein D gene: regulatory roles of AP-1, forkhead box, and GT box binding proteins.
Lung Injury
Radiation-induced lung injury and inflammation in mice: role of inducible nitric oxide synthase and surfactant protein d.
Lung Injury
Surfactant Protein D Dampens Lung Injury by Suppressing NLRP3 Inflammasome Activation and NF-?B Signaling in Acute Pancreatitis.
Lung Injury
Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis.
Lung Injury
Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure.
Lung Injury
The effectiveness of the serum surfactant protein D (Sp-D) level to indicate lung injury in pulmonary embolism.
Lung Injury
The evaluation of serum surfactant protein D (SP-D) levels as a biomarker of lung injury in tuberculosis and different lung diseases.
Lung Injury
[Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux].
Lung Injury
[Research of the biomarkers in pulmonary and extrapulmonary acute respiratory distress syndrome].
Lung Neoplasms
Association between genetic variations in surfactant protein d and emphysema, interstitial pneumonia, and lung cancer in a Japanese population.
Lung Neoplasms
Correlation analysis of surfactant protein A and surfactant protein D with lung function in exhaled breath condensate from lung cancer patients with and without COPD.
Lung Neoplasms
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Lung Neoplasms
Surfactant protein D and bronchial dysplasia in smokers at high risk of lung cancer.
Lung Neoplasms
Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling.
Lung Neoplasms
[Expression and clinical significance of surfactant protein D mRNA in peripheral blood of lung cancer patients]
Lung Neoplasms
[Joint serum tumor markers serve as survival predictive model of erlotinib in the treatment of recurrent non-small cell lung cancer].
Lupus Erythematosus, Systemic
Circulating Surfactant Protein D Is Decreased in Systemic Lupus Erythematosus.
Lupus Erythematosus, Systemic
The Possible Effect of B-Cell Epitopes of Epstein-Barr Virus Early Antigen, Membrane Antigen, Latent Membrane Protein-1, and -2A on Systemic Lupus Erythematosus.
Measles
Clinical significance of the serum surfactant protein D and KL-6 levels in patients with measles complicated by interstitial pneumonia.
Measles
Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
Mycobacterium Infections
Potential of Ca(2+) in Mycobacterium tuberculosis H37Rv Pathogenesis and Survival.
Nasal Polyps
[Expression and significance of pulmonary surfactant protein D and IL-16 in allergic rhinitis and nasal polyps].
Neoplasm Metastasis
Association of surfactant protein D with pulmonary metastases from colon cancer.
Neoplasm Metastasis
Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis.
Neoplasm Metastasis
GDPD5, a target of miR-195-5p, is associated with metastasis and chemoresistance in colorectal cancer.
Neoplasm Metastasis
High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer.
Neoplasms
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Neoplasms
Antibody against Haemophilus influenzae protein D in patients with chronic conditions causing secondary immunodeficiency.
Neoplasms
Biological subphenotypes of acute respiratory distress syndrome may not reflect differences in alveolar inflammation.
Neoplasms
Blood Specimen Biomarkers of Inflammation, Matrix Degradation, Angiogenesis, and Cardiac Involvement: a Future Useful Tool in Assessing Clinical Outcomes of COPD Patients in Clinical Practice?
Neoplasms
Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis.
Neoplasms
Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities.
Neoplasms
Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
Neoplasms
Correlation between peripheral skeletal muscle functions and the stable phase of COPD in older patients.
Neoplasms
EDI3 links choline metabolism to integrin expression, cell adhesion and spreading.
Neoplasms
Effect of Driving Pressure Change During Extracorporeal Membrane Oxygenation in Adults With Acute Respiratory Distress Syndrome: A Randomized Crossover Physiologic Study.
Neoplasms
Effect of lung surfactant collectins on bronchoalveolar macrophage interaction with Blastomyces dermatitidis: inhibition of tumor necrosis factor alpha production by surfactant protein D.
Neoplasms
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Neoplasms
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.
Neoplasms
High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer.
Neoplasms
Human SP-D Acts as an Innate Immune Surveillance Molecule Against Androgen-Responsive and Androgen-Resistant Prostate Cancer Cells.
Neoplasms
Hyaluronic Acid Present in the Tumor Microenvironment Can Negate the Pro-apototic Effect of a Recombinant Fragment of Human Surfactant Protein D on Breast Cancer Cells.
Neoplasms
Inflammatory parameters and pulmonary biomarkers in smokers with and without chronic obstructive pulmonary disease (COPD).
Neoplasms
Opposite effects of tumor protein D (TPD) 52 and TPD54 on oral squamous cell carcinoma cells.
Neoplasms
Pathological Significance and Prognostic Value of Surfactant Protein D in Cancer.
Neoplasms
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Neoplasms
Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study.
Neoplasms
Serum levels of surfactant protein D are increased in mice with lung tumors.
Neoplasms
Silencing of the glycerophosphocholine phosphodiesterase GDPD5 alters the phospholipid metabolite profile in a breast cancer model in vivo as monitored by (31) P MRS.
Neoplasms
The Association between Body Mass Index and Plasma Cytokine Levels in Patients with Acute Lung Injury.
Neoplasms
The role of total bile acid in oral secretions in ventilator-associated pneumonia.
Neoplasms
Tumor Proteins D52 and D54 Have Opposite Effects on the Terminal Differentiation of Chondrocytes.
Neoplasms
[Expression and clinical significance of surfactant protein D mRNA in peripheral blood of lung cancer patients]
Neoplasms
[Systemic inflammation in patients with chronic obstructive pulmonary disease and obesity].
Neoplastic Cells, Circulating
[Expression and clinical significance of surfactant protein D mRNA in peripheral blood of lung cancer patients]
Neuroblastoma
Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome.
Obesity
Genetic variations of the bitter taste receptor TAS2R38 are associated with obesity and impact on single immune traits.
Obesity
Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application.
Obesity
Surfactant protein D of the innate immune defence is inversely associated with human obesity and SP-D deficiency infers increased body weight in mice.
Otitis
Bactericidal antibody response against P6, protein D, and OMP26 of nontypeable Haemophilus influenzae after acute otitis media in otitis-prone children.
Otitis
Experimental recurrent otitis media induced by Haemophilus influenzae: protection and serum antibodies.
Otitis
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
Otitis
Protein D, the glycerophosphodiester phosphodiesterase from Haemophilus influenzae with affinity for human immunoglobulin D, influences virulence in a rat otitis model.
Otitis
Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine.
Otitis
Serum antibody response to three non-typeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children.
Otitis
The Effect of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine on H. influenzae in Healthy Carriers and Middle Ear Infections in Iceland.
Otitis Media
10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial.
Otitis Media
10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.
Otitis Media
Abrogation of nontypeable Haemophilus influenzae protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media.
Otitis Media
Bactericidal antibody response against P6, protein D, and OMP26 of nontypeable Haemophilus influenzae after acute otitis media in otitis-prone children.
Otitis Media
Current and Future Prospects for a Vaccine for Nontypeable Haemophilus influenzae.
Otitis Media
Decreased Acute Otitis Media With Treatment Failure After Introduction of the Ten-valent Pneumococcal Haemophilus influenzae Protein D Conjugate Vaccine.
Otitis Media
Developing a vaccine to prevent otitis media caused by nontypeable Haemophilus influenzae.
Otitis Media
Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
Otitis Media
ELISA IgG concentrations and opsonophagocytic activity following pneumococcal protein D conjugate vaccination and relationship to efficacy against acute otitis media.
Otitis Media
Haemophilus influenzae-protein D specific antibody correlate with protection against acute otitis media in young children.
Otitis Media
Higher levels of mucosal antibody to pneumococcal vaccine candidate proteins are associated with reduced acute otitis media caused by Streptococcus pneumoniae in young children.
Otitis Media
Impact of different case definitions for acute otitis media on the efficacy estimates of a pneumococcal conjugate vaccine.
Otitis Media
Local and systemic antibody levels against protein D of Haemophilus influenzae following immunization and infection in rats.
Otitis Media
Nasopharyngeal carriage of otitis media pathogens in infants receiving 10-valent non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10), 13-valent pneumococcal conjugate vaccine (PCV13) or a mixed primary schedule of both vaccines: A randomised controlled trial.
Otitis Media
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6?months: PREVIX_COMBO, a 3-arm randomised controlled trial.
Otitis Media
Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae.
Otitis Media
Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
Otitis Media
Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations.
Otitis Media
Substrate binding protein SBP2 of a putative ABC transporter as a novel vaccine antigen of Moraxella catarrhalis.
Otitis Media
The Effect of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine on H. influenzae in Healthy Carriers and Middle Ear Infections in Iceland.
Ovarian Neoplasms
Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer.
Overweight
Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application.
Pancreatic Neoplasms
A Recombinant Fragment of Human Surfactant Protein D induces Apoptosis in Pancreatic Cancer Cell Lines via Fas-Mediated Pathway.
Pancreatic Neoplasms
Human Surfactant Protein D Suppresses Epithelial-to-Mesenchymal Transition in Pancreatic Cancer Cells by Downregulating TGF-?.
Pancreatitis
Surfactant Protein D Dampens Lung Injury by Suppressing NLRP3 Inflammasome Activation and NF-?B Signaling in Acute Pancreatitis.
Plague
Antigenic profiling of yersinia pestis infection in the Wyoming coyote (Canis latrans).
Pneumococcal Infections
Biophysical Characterization and Thermal Stability of Pneumococcal Histidine Triad Protein D in the Presence of Zinc and Manganese.
Pneumococcal Infections
Cost-effectiveness evaluation of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine for children in Taiwan.
Pneumococcal Infections
Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
Pneumococcal Infections
Effectiveness of the 10-valent pneumococcal conjugate vaccine among girls, boys, preterm and low-birth-weight infants - Results from a randomized, double-blind vaccine trial.
Pneumococcal Infections
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
Pneumococcal Infections
Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada.
Pneumococcal Infections
Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae.
Pneumococcal Infections
Overall effectiveness of pneumococcal conjugate vaccines: an economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
Pneumococcal Infections
Protection against pneumococcal infection elicited by immunization with glutamyl tRNA synthetase, polyamine transport protein D and sortase A.
Pneumococcal Infections
Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study.
Pneumococcal Infections
Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.
Pneumoconiosis
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
Pneumocystis Infections
Surfactant protein D enhances Pneumocystis infection in immune-suppressed mice.
Pneumonia
Accumulation of surfactant protein D in the lung during Pneumocystis carinii pneumonia.
Pneumonia
Carbohydrate recognition domain of surfactant protein D mediates interactions with Pneumocystis carinii glycoprotein A.
Pneumonia
CD4+ T-cell responses among adults and young children in response to Streptococcus pneumoniae and Haemophilus influenzae vaccine candidate protein antigens.
Pneumonia
Children with absent surfactant protein D in bronchoalveolar lavage have more frequently pneumonia.
Pneumonia
Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study.
Pneumonia
Comparative evaluation of heterologous production systems for recombinant pulmonary surfactant protein D.
Pneumonia
Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis.
Pneumonia
Development of an enzyme-linked immunosorbent assay for measurement of rat pulmonary surfactant protein D using monoclonal antibodies.
Pneumonia
Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
Pneumonia
Examination of Surfactant Protein D as a Biomarker for Evaluating Pulmonary Toxicity of Nanomaterials in Rat.
Pneumonia
HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D.
Pneumonia
Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction.
Pneumonia
Increased serum SP-D in identification of high-risk smokers at high risk of COPD.
Pneumonia
New Biomarkers to Diagnose Ventilator Associated Pneumonia: Pentraxin 3 and Surfactant Protein D.
Pneumonia
Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation.
Pneumonia
Restoration of lung surfactant protein D by IL-6 protects against secondary pneumonia following hemorrhagic shock.
Pneumonia
S-nitrosylation of surfactant protein D as a modulator of pulmonary inflammation.
Pneumonia
Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia small star, filled.
Pneumonia
Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia.
Pneumonia
Surfactant Protein D Deficiency Aggravates Cigarette Smoke-Induced Lung Inflammation by Upregulation of Ceramide Synthesis.
Pneumonia
Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages.
Pneumonia
Surfactant protein D: a predictor for severity of community-acquired pneumonia in children.
Pneumonia
Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
Pneumonia
Update on Molecular Mechanisms of Corticosteroid Resistance in Chronic Obstructive Pulmonary Disease.
Pneumonia
[Increased level of KL-6 in a BJP-?-type multiple myeloma patient with poor prognosis].
Pneumonia, Bacterial
Evaluation of serum amyloid a and surfactant protein D in sera for identification of the clinical condition of horses with bacterial pneumonia.
Pneumonia, Bacterial
Surfactant protein D: a useful marker for differentiation of drug-induced pneumonia and bacterial pneumonia.
Pneumonia, Pneumococcal
The role of surfactant protein D in the colonisation of the respiratory tract and onset of bacteraemia during pneumococcal pneumonia.
Pneumonia, Pneumocystis
Accumulation of surfactant protein D in the lung during Pneumocystis carinii pneumonia.
Pneumonia, Pneumocystis
Carbohydrate recognition domain of surfactant protein D mediates interactions with Pneumocystis carinii glycoprotein A.
Pneumonia, Pneumocystis
Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia.
Pneumonia, Pneumocystis
Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages.
Pneumonia, Ventilator-Associated
Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.
Poliomyelitis
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Pre-Eclampsia
Differential levels of surfactant protein A, surfactant protein D, and progesterone to estradiol ratio in maternal serum before and after the onset of severe early-onset preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Surfactant protein D and KL-6 as serologic indicators of Pneumocystis carinii pneumonia in a child with acute lymphoblastic leukemia.
Premature Birth
A study of collectin genes in spontaneous preterm birth reveals an association with a common surfactant protein D gene polymorphism.
Premature Birth
Genetic associations of surfactant protein D and angiotensin-converting enzyme with lung disease in preterm neonates.
Premature Birth
Surfactant protein D modulates levels of IL-10 and TNF-? in intrauterine compartments during lipopolysaccharide-induced preterm birth.
Prostatic Neoplasms
Membrane Interactome of a Recombinant Fragment of Human Surfactant Protein D Reveals GRP78 as a Novel Binding Partner in PC3, a Metastatic Prostate Cancer Cell Line.
Pulmonary Alveolar Proteinosis
Accumulation of surfactant protein D in human pulmonary alveolar proteinosis.
Pulmonary Alveolar Proteinosis
Clinical importance of bronchoalveolar lavage fluid and blood cytokines, surfactant protein D, and Kerbs von Lungren 6 antigen in idiopathic pulmonary alveolar proteinosis.
Pulmonary Alveolar Proteinosis
Lung surfactant levels are regulated by Ig-Hepta/GPR116 by monitoring surfactant protein D.
Pulmonary Alveolar Proteinosis
Structure and activity of human surfactant protein D from different natural sources.
Pulmonary Atelectasis
A case of progressive orthopnoea and shoulder pain secondary to bilateral diaphragmatic paralysis.
Pulmonary Disease, Chronic Obstructive
Association of Surfactant-Associated Protein D Gene Polymorphisms with the Risk of COPD: a Meta-Analysis.
Pulmonary Disease, Chronic Obstructive
Biomarkers for chronic obstructive pulmonary disease: surfactant protein D and C-reactive protein.
Pulmonary Disease, Chronic Obstructive
Chronic obstructive pulmonary disease and inhaled steroids alter surfactant protein D (SP-D) levels: a cross-sectional study.
Pulmonary Disease, Chronic Obstructive
Cigarette smoking prior to blood sampling acutely affects serum levels of the chronic obstructive pulmonary disease biomarker surfactant protein D.
Pulmonary Disease, Chronic Obstructive
Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study.
Pulmonary Disease, Chronic Obstructive
Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD.
Pulmonary Disease, Chronic Obstructive
Comprehensive analysis of gene-expression profile in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Comprehensive characterisation of pulmonary and serum surfactant protein D in COPD.
Pulmonary Disease, Chronic Obstructive
Correlation analysis of surfactant protein A and surfactant protein D with lung function in exhaled breath condensate from lung cancer patients with and without COPD.
Pulmonary Disease, Chronic Obstructive
Effect of Single versus Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis.
Pulmonary Disease, Chronic Obstructive
Evaluation of full-length, cleaved and nitrosylated serum surfactant protein D as biomarkers for COPD.
Pulmonary Disease, Chronic Obstructive
Genetic Polymorphisms of Surfactant Protein D rs2243639, Interleukin (IL)-1? rs16944 and IL-1RN rs2234663 in Chronic Obstructive Pulmonary Disease, Healthy Smokers, and Non-Smokers.
Pulmonary Disease, Chronic Obstructive
Genetic Variants in IL6R and ADAM19 are Associated with COPD Severity in a Mexican Mestizo Population.
Pulmonary Disease, Chronic Obstructive
Increased MMP8 Levels in Atopic Chronic Obstructive Pulmonary Disease: A Study Testing Multiple Immune Factors in Atopic and Non-Atopic Patients.
Pulmonary Disease, Chronic Obstructive
Integrating lung and plasma expression of pneumo-proteins in developing biomarkers in COPD: a case study of surfactant protein D.
Pulmonary Disease, Chronic Obstructive
Involvement of surfactant protein D in emphysema revealed by genetic association study.
Pulmonary Disease, Chronic Obstructive
Nicotinic acetylcholine receptors (rs1051730) gene polymorphism and surfactant protein D level in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Non-typeable Haemophilus influenzae protein vaccine in adults with COPD: A phase 2 clinical trial.
Pulmonary Disease, Chronic Obstructive
Perinatal biomarkers implying 'Developmental Origins of Health and Disease' consequences in intrauterine growth restriction.
Pulmonary Disease, Chronic Obstructive
Polymorphisms in Surfactant Protein D are Associated with COPD.
Pulmonary Disease, Chronic Obstructive
Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Pulmonary Disease, Chronic Obstructive
Role of serum and induced sputum surfactant protein D in predicting the response to treatment in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial.
Pulmonary Disease, Chronic Obstructive
Serum surfactant protein D during acute exacerbations of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Serum Surfactant Protein D is a Potential Biomarker for Chronic Obstructive Pulmonary Disease: a Systematic Review and Meta-analysis.
Pulmonary Disease, Chronic Obstructive
Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD.
Pulmonary Disease, Chronic Obstructive
Serum surfactant protein D, lung function decline, and incident chronic obstructive pulmonary disease: a longitudinal study in Beijing.
Pulmonary Disease, Chronic Obstructive
Serum surfactant protein D: biomarker of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Simvastatin Therapy and Bronchoalveolar Lavage Fluid Biomarkers in Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
Smoking reduces surfactant protein D and phospholipids in patients with and without chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
SNP rs3088308 is a risk factor for poor lung function in healthy smokers.
Pulmonary Disease, Chronic Obstructive
Surfactant protein D as a biomarker for chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Surfactant protein D in chornic obstructive pulmonary disease (COPD).
Pulmonary Disease, Chronic Obstructive
Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation.
Pulmonary Disease, Chronic Obstructive
Surfactant protein D multimerization and gene polymorphism in COPD and asthma.
Pulmonary Disease, Chronic Obstructive
Surfactant protein D, a clinical biomarker for chronic obstructive pulmonary disease with excellent discriminant values.
Pulmonary Disease, Chronic Obstructive
Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease.
Pulmonary Disease, Chronic Obstructive
Surfactant protein d, soluble intercellular adhesion molecule-1 and high-sensitivity C-reactive protein as biomarkers of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Systematic Review and Meta-Analysis Confirms Significant Contribution of Surfactant Protein D in Chronic Obstructive Pulmonary Disease.
Pulmonary Disease, Chronic Obstructive
The Effect of Intrauterine Growth Restriction on Circulating Surfactant Protein D Concentrations in the Perinatal Period.
Pulmonary Disease, Chronic Obstructive
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.
Pulmonary Disease, Chronic Obstructive
The PROTECCT-M study: a cohort study investigating associations between novel specific biomarkers, patient-related, healthcare system markers and the trajectory of COPD patients treated in primary care.
Pulmonary Disease, Chronic Obstructive
The relationship between serum levels of surfactant protein D in COPD exacerbation severity and mortality
Pulmonary Disease, Chronic Obstructive
The role of serum surfactant protein D as a biomarker of exacerbation of chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease.
Pulmonary Disease, Chronic Obstructive
[Effect of basic therapy on clinical symptoms, quality of life and systemic inflammation in patients with chronic obstructive pulmonary disease].
Pulmonary Edema
Prognostic value of surfactant proteins A and D in patients with acute lung injury.
Pulmonary Embolism
The effectiveness of the serum surfactant protein D (Sp-D) level to indicate lung injury in pulmonary embolism.
Pulmonary Emphysema
A recombinant fragment of human surfactant protein D reduces alveolar macrophage apoptosis and pro-inflammatory cytokines in mice developing pulmonary emphysema.
Pulmonary Emphysema
Surfactant protein D regulates NF-kappa B and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways.
Pulmonary Fibrosis
Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Pulmonary Fibrosis
Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Pulmonary Fibrosis
Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Pulmonary Fibrosis
Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Pulmonary Fibrosis
The Diagnostic Value of the Interstitial Biomarkers KL-6 and SP-D for the Degree of Fibrosis in Combined Pulmonary Fibrosis and Emphysema.
Pulmonary Fibrosis
[Clinical value of surfactant protein D as a biomarker of pulmonary fibrosis in patients with scleroderma systematica in relation to the presence of gastroesophageal reflux].
Radiation Fibrosis Syndrome
Monoclonal antibodies to surfactant protein D: evaluation of immunoreactivity in normal rat lung and in a radiation-induced fibrosis model.
Radiation Pneumonitis
Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy.
Radiation Pneumonitis
Measurement of exhaled nitric oxide and serum surfactant protein D levels for monitoring radiation pneumonitis following thoracic radiotherapy.
Radiation Pneumonitis
Radiation pneumonitis after stereotactic radiation therapy for lung cancer.
Renal Insufficiency, Chronic
Serum surfactant protein D is associated with the prognosis in patients with chronic kidney disease.
Reperfusion Injury
Change of surfactant protein D and A after renal ischemia reperfusion injury.
Reproductive Tract Infections
The Chlamydia trachomatis PmpD adhesin forms higher order structures through disulphide-mediated covalent interactions.
Respiratory Distress Syndrome
Evaluation of Lung Injury in Infants with Congenital Diaphragmatic Hernia.
Respiratory Distress Syndrome
Hypoxemic Patients With Bilateral Infiltrates Treated With High-Flow Nasal Cannula Present a Similar Pattern of Biomarkers of Inflammation and Injury to Acute Respiratory Distress Syndrome Patients.
Respiratory Distress Syndrome
Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity.
Respiratory Distress Syndrome
Surfactant Protein D Is Altered in Experimental Malaria-Associated Acute Lung Injury/Acute Respiratory Distress Syndrome.
Respiratory Distress Syndrome
Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure.
Respiratory Distress Syndrome
The Association between Body Mass Index and Plasma Cytokine Levels in Patients with Acute Lung Injury.
Respiratory Distress Syndrome
[Serial changes in biomarkers in pulmonary and extrapulmonary acute respiratory distress syndrome].
Respiratory Insufficiency
Association of patient weight status with plasma surfactant protein D, a biomarker of alveolar epithelial injury, in children with acute respiratory failure.
Respiratory Syncytial Virus Infections
A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo.
Respiratory Syncytial Virus Infections
Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection.
Respiratory Tract Infections
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
Respiratory Tract Infections
Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures.
Respiratory Tract Infections
Impact of surfactant protein D, interleukin-5, and eosinophilia on Cryptococcosis.
Respiratory Tract Infections
Respiratory tract infections in diabetic and non-diabetic individuals are linked with serum surfactant protein-D.
Respiratory Tract Infections
The Effect of Intrauterine Growth Restriction on Circulating Surfactant Protein D Concentrations in the Perinatal Period.
Rhinitis, Allergic
Association between single nucleotide polymorphisms of surfactant protein D and allergic rhinitis in Chinese patients.
Rhinitis, Allergic
[Expression and significance of pulmonary surfactant protein D and IL-16 in allergic rhinitis and nasal polyps].
Sarcoidosis
Concentration of surfactant protein D, Clara cell protein CC-16 and IL-10 in bronchoalveolar lavage (BAL) in patients with sarcoidosis, hypersensivity pneumonitis and idiopathic pulmonary fibrosis.
Sarcoidosis
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis.
Sarcoidosis
Prognostic significance of surfactant protein A, surfactant protein D, Clara cell protein 16, S100 protein, trefoil factor 3, and prostatic secretory protein 94 in idiopathic pulmonary fibrosis, sarcoidosis, and chronic pulmonary obstructive disease.
Scleroderma, Systemic
Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?
Scleroderma, Systemic
Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Scleroderma, Systemic
Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
Scleroderma, Systemic
Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Scleroderma, Systemic
Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Scleroderma, Systemic
Serum surfactant protein D and exhaled nitric oxide as biomarkers of early lung damage in systemic sclerosis.
Scleroderma, Systemic
Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
Sepsis
MEG3 Alleviated LPS-Induced Intestinal Injury in Sepsis by Modulating miR-129-5p and Surfactant Protein D.
Sepsis
miR-182-5p contributes to intestinal injury in a murine model of Staphylococcus aureus pneumonia-induced sepsis via targeting surfactant protein D.
Sepsis
miR-199a-5p Exacerbated Intestinal Barrier Dysfunction through Inhibiting Surfactant Protein D and Activating NF-?B Pathway in Sepsis.
Sepsis
S1P lyase inhibition protects against sepsis by promoting disease tolerance via the S1P/S1PR3 axis.
Sepsis
Surfactant protein D (SP-D) gene polymorphism rs721917 is an independent predictor of acute kidney injury development in sepsis patients: a prospective cohort study.
Sepsis
Surfactant protein D attenuates acute lung and kidney injuries in pneumonia-induced sepsis through modulating apoptosis, inflammation and NF-?B signaling.
Sexually Transmitted Diseases
From the Cover: Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen.
Shock, Septic
Association of type II secretory phospholipase A2 and surfactant protein D with the pulmonary oxygenation potential in patients with septic shock during polymyxin-B immobilized fiber-direct hemoperfusion.
Shock, Septic
Intratracheal recombinant surfactant protein d prevents endotoxin shock in the newborn preterm lamb.
Silicosis
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
Silicosis
[Association of surfactant protein D gene polymorphisms at rs3088308 and rs721917 with susceptibility to silicosis].
Sleep Apnea, Obstructive
Potential inflammatory markers in obstructive sleep apnea-hypopnea syndrome.
Spinocerebellar Ataxias
Phospholipid-metabolizing enzymes in Alzheimer's disease: increased lysophospholipid acyltransferase activity and decreased phospholipase A2 activity.
Squamous Cell Carcinoma of Head and Neck
Opposite effects of tumor protein D (TPD) 52 and TPD54 on oral squamous cell carcinoma cells.
Staphylococcal Infections
Protective Role of Surfactant Protein D in Ocular Staphylococcus aureus Infection.
Suppuration
Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine.
Tetanus
A physico-chemical assessment of the thermal stability of pneumococcal conjugate vaccine components.
Tetanus
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
Tetanus
Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial.
Tetanus
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Tetanus
Protein carriers of conjugate vaccines: Characteristics, development and clinical trials.
Tetanus
Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Tetanus
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Tetanus
The short-term impact of each primary dose of pneumococcal conjugate vaccine on nasopharyngeal carriage: Systematic review and meta-analyses of randomised controlled trials.
Trachoma
From the Cover: Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen.
Tuberculosis
Critical Role of Amino Acid Position 343 of Surfactant Protein-D in the Selective Binding of Glycolipids from Mycobacterium tuberculosis.
Tuberculosis
Functional Analysis of Genetic Variations in Surfactant Protein D in Mycobacterial Infection and Their Association With Tuberculosis.
Tuberculosis
Paediatric and adult bronchiectasis: Vaccination in prevention and management.
Tuberculosis
Surfactant protein D binds to Mycobacterium tuberculosis bacilli and lipoarabinomannan via carbohydrate-lectin interactions resulting in reduced phagocytosis of the bacteria by macrophages.
Tuberculosis
Surfactant protein D increases fusion of Mycobacterium tuberculosis-containing phagosomes with lysosomes in human macrophages.
Tuberculosis
Surfactant protein D inhibition of human macrophage uptake of Mycobacterium tuberculosis is independent of bacterial agglutination.
Tuberculosis
The evaluation of serum surfactant protein D (SP-D) levels as a biomarker of lung injury in tuberculosis and different lung diseases.
Turner Syndrome
The effects of GH and hormone replacement therapy on serum concentrations of mannan-binding lectin, surfactant protein D and vitamin D binding protein in Turner syndrome.
Uveitis
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis.
Vaccinia
Protective effect of surfactant protein d in pulmonary vaccinia virus infection: implication of a27 viral protein.
Vascular Diseases
Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Ventilator-Induced Lung Injury
Increased prevalence of low oligomeric state surfactant protein D with restricted lectin activity in bronchoalveolar lavage fluid from preterm infants.
Virus Diseases
A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo.
Virus Diseases
Hapivirins and Diprovirins: Novel ?-Defensin Analogs with Potent Activity against Influenza A Virus.
Virus Diseases
Protective effect of surfactant protein d in pulmonary vaccinia virus infection: implication of a27 viral protein.
Virus Diseases
Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.
Virus Diseases
Pulmonary Surfactant Protein D in First-Line Innate Defence against Influenza A Virus Infections.
Virus Diseases
Serum Surfactant Protein D (SP-D) is a Prognostic Marker of Poor Outcome in Patients with A/H1N1 Virus Infection.
Virus Diseases
Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection.
Whooping Cough
Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.
Whooping Cough
Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
Whooping Cough
Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Whooping Cough
Paediatric and adult bronchiectasis: Vaccination in prevention and management.
Whooping Cough
Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.
Whooping Cough
Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines.
Yellow Fever
Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
the cells show a 2-4fold activation of glycerophosphocholine-phosphodiesterase compared to control cells
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
-
altered phosphatidylcholine metabolism in epithelial ovarian cancer cells leads to 2-4fold increased enzyme activity
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). GDPD5_HUMAN
605
6
68586
Swiss-Prot
Mitochondrion (Reliability: 5)
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
medicine
enzyme inhibition represents a targeting strategy in the treatment of breast cancer
diagnostics
-
increased enzyme activity due to altered phosphatidylcholine metabolism in epithelial ovarian cancer cells can serve as diagnostic marker, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Ross, B.M.; Sherwin, A.L.; Kish, S.J.
Multiple forms of the enzyme glycerophosphodiesterase are present in human brain
Lipids
30
1075-1081
1995
Homo sapiens
brenda
Iorio, E.; Ricci, A.; Bagnoli, M.; Pisanu, M.E.; Castellano, G.; Di Vito, M.; Venturini, E.; Glunde, K.; Bhujwalla, Z.M.; Mezzanzanica, D.; Canevari, S.; Podo, F.
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells
Cancer Res.
70
2126-2135
2010
Homo sapiens
brenda
Marchan, R.
GDPD5, a choline-generating enzyme and its novel role in tumor cell migration
Arch. Toxicol.
90
3143-3144
2016
Homo sapiens (Q8WTR4)
brenda
EXTERNAL LINKS (specific for EC-Number 3.1.4.2)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
About BRENDA
Social media
Help
Survey
Download
Contribution
Legal
Curated at
Member of
